Astorg plans to combine two of its portfolio companies, proposing that Oxoid Remel Microbiology acquire the microbiology diagnostics division of Solabia, which includes Biokar Diagnostics. The move aims to create a leading global microbiology platform serving clinical diagnostics, food safety and pharmaceutical testing markets. The deal builds on Astorg's acquisition of Oxoid Remel Microbiology from Thermo Fisher Scientific in August 2026, which includes diagnostic consumables and equipment for microbiological testing across clinical, food and beverage, and pharmaceutical industries. Solabia's division brings complementary expertise in microbiological culture media, particularly for food and beverage testing. According to Astorg, combining the two product portfolios and customer relationships would enable cross-selling opportunities, widen offerings across testing applications and reach new markets.
"Drawing on our deep sector expertise, we have identified an opportunity to bring together two highly complementary businesses to create a focused global microbiology platform," said Judith Charpentier, co-managing partner and head of healthcare at Astorg, and Olivier Lieven, partner at Astorg.
The divestment is part of Solabia's strategic repositioning to sharpen its focus on cosmetics, nutrition and life sciences. Solabia recently acquired Mibelle Biochemistry in June 2026 and appointed Muriel Koch, former CEO of Groupe NUXE, as president and CEO from October 29, 2026, succeeding Jean-Baptiste Dellon. Financial terms were not disclosed, and the transaction remains subject to regulatory approvals and definitive agreements.
Source: PE Hub · Summarized by HeadlinesBriefing